A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD001 in Healthy Subjects

Inclusion Criteria: * Males and females using suitable methods of contraception, or females of non-childbearing potential * Consent to study participation * Body weight ≥ 50 kg and body mass index 19 - 30 kg/m2 * Vital sign assessments within the normal ranges * Healthy as determined following physical and laboratory examinations at screening visit * Spirometry readings (FEV1 and FVC) to be ≥ 80% of predicted value Exclusion Criteria: * Acute or chronic illness detected at the screening visit * Respiratory tract infection within 4 weeks of the screening visit * Use of prescribed or OTC medication within 14 days of the screening visit * History of regular alcohol use over the recommended limits within 6 months of screening, or history/evidence of alcohol or drug abuse * Smoker or use of tobacco products within 6 months of screening * Abnormal blood or urine laboratory test results at screening * Recent participation (within 3 months) in another clinical trial * Current, or history of, allergy that may be contraindicated